A significant breakthrough in understanding IgA nephropathy – a leading cause of kidney disease – has emerged from research at Fujita Health University in Japan. Scientists have identified complement factor H-related protein 1 (CFHR1) as a key player in the disease’s progression, offering a potential new diagnostic marker and opening doors for targeted therapies. This … Read more
Gilead Sciences Expands Autoimmune Disease Portfolio with $1.7 Billion Ouro Medicines Acquisition In a significant move to bolster its presence in the rapidly evolving field of autoimmune disease treatment, Gilead Sciences has announced the acquisition of Ouro Medicines, a privately held biotechnology company pioneering novel T cell engager therapies. The deal, valued at $1.7 billion, … Read more
The decades-long struggle to objectively diagnose and treat mental illness may be entering a new era. A recent paper from the American Psychiatric Association (APA) signals a potential paradigm shift: the incorporation of biomarkers – measurable biological indicators – into the Diagnostic and Statistical Manual of Mental Disorders (DSM), the field’s foundational text. This isn’t … Read more
The relentless search for the root causes of multiple sclerosis (MS) has taken a significant turn, with new research from UCSF pointing to a potentially crucial role for the Epstein-Barr virus (EBV) and a specific type of immune cell. This isn’t simply confirming EBV’s presence – long known to be nearly universal in MS patients … Read more
A breakthrough discovery from Oregon Health & Science University offers a beacon of hope for individuals battling a devastating, and often misdiagnosed, autoimmune brain disease. Researchers have pinpointed a specific target on the NMDA receptor – a critical component of brain function – that, if blocked, could halt or even reverse the disease’s progression. This … Read more